Citius Oncology, Inc.
CTOR
$1.13
$0.010.89%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -9.27% | -7.51% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.72% | -33.81% | |||
| Operating Income | 4.72% | 33.81% | |||
| Income Before Tax | 7.31% | 31.66% | |||
| Income Tax Expenses | 0.00% | 0.00% | |||
| Earnings from Continuing Operations | 6.95% | 30.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.95% | 30.58% | |||
| EBIT | 4.72% | 33.81% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 15.07% | 30.62% | |||
| Normalized Basic EPS | 15.47% | 31.70% | |||
| EPS Diluted | 15.07% | 30.62% | |||
| Normalized Diluted EPS | 15.47% | 31.70% | |||
| Average Basic Shares Outstanding | 9.59% | 0.00% | |||
| Average Diluted Shares Outstanding | 9.59% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||